Teva reports growth in fourth quarter and full year 2023

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) today reported results for the year and the quarter ended december 31, 2023. q4 2023 and full year 2023 highlights:   q4 2023 fy 2023 revenues   $4.5 billion $15.8 billion gaap diluted earnings (loss) per share   $0.41 $(0.50) non-gaap diluted eps   $1.00 $2.56 cash flow generated from operating activities   $1,184 million $1,368 million free cash flow   $1,486 million $2,387 million mr. richard francis.
TEVA Ratings Summary
TEVA Quant Ranking